182 related articles for article (PubMed ID: 25071879)
1. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
van Gool MH; Aukema TS; Hartemink KJ; Valdés Olmos RA; van Tinteren H; Klomp HM
World J Radiol; 2014 Jul; 6(7):392-8. PubMed ID: 25071879
[TBL] [Abstract][Full Text] [Related]
2. CD147-mediated glucose metabolic regulation contributes to the predictive role of
Li X; Fu Q; Zhu Y; Wang J; Liu J; Yu X; Xu W
Mol Carcinog; 2019 Feb; 58(2):247-257. PubMed ID: 30320488
[TBL] [Abstract][Full Text] [Related]
3. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
[TBL] [Abstract][Full Text] [Related]
4. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
[TBL] [Abstract][Full Text] [Related]
5. Tumor heterogeneity on (18)F-FDG-PET/CT for response monitoring in non-small cell lung cancer treated with erlotinib.
van Gool MH; Aukema TS; Sinaasappel M; Valdés Olmos RA; Klomp HM
J Thorac Dis; 2016 Mar; 8(3):E200-3. PubMed ID: 27076970
[TBL] [Abstract][Full Text] [Related]
6. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
7. Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients.
Winther-Larsen A; Fledelius J; Demuth C; Bylov CM; Meldgaard P; Sorensen BS
Transl Oncol; 2016 Dec; 9(6):505-511. PubMed ID: 27816687
[TBL] [Abstract][Full Text] [Related]
8. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
9. The Prognostic Value of
Agüloğlu N; Akyol M; Kömek H; Katgı N
Mol Imaging Radionucl Ther; 2022 Jun; 31(2):104-113. PubMed ID: 35770976
[TBL] [Abstract][Full Text] [Related]
10.
Huang YE; Tsai YH; Huang YJ; Lung JH; Ho KW; Yen TC; Chan SC; Chen ST; Tsai MF; Hung MS
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326662
[TBL] [Abstract][Full Text] [Related]
11. [Current Status and Progress in Molecular Imaging of Non-small Cell Lung
Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and
Treatment Tolerance Prediction].
Dai D; Xu W; Wang Q; Li X; Zhu Y
Zhongguo Fei Ai Za Zhi; 2017 Dec; 20(12):852-856. PubMed ID: 29277186
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07).
Montemurro M; Cioffi A; Dômont J; Rutkowski P; Roth AD; von Moos R; Inauen R; Toulmonde M; Burkhard RO; Knuesli C; Bauer S; Cassier P; Schwarb H; Le Cesne A; Koeberle D; Bärtschi D; Dietrich D; Biaggi C; Prior J; Leyvraz S
Cancer; 2018 Apr; 124(7):1449-1454. PubMed ID: 29315500
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Sunaga N; Oriuchi N; Kaira K; Yanagitani N; Tomizawa Y; Hisada T; Ishizuka T; Endo K; Mori M
Lung Cancer; 2008 Feb; 59(2):203-10. PubMed ID: 17913282
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
15.
Gao XC; Wei CH; Zhang RG; Cai Q; He Y; Tong F; Dong JH; Wu G; Dong XR
Oncol Lett; 2020 Oct; 20(4):61. PubMed ID: 32863894
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Correlation Between Epidermal Growth Factor Receptor Mutation Status and
Jiang M; Zhang X; Chen Y; Chen P; Guo X; Ma L; Gao Q; Mei W; Zhang J; Zheng J
Front Oncol; 2022; 12():780186. PubMed ID: 35515138
[TBL] [Abstract][Full Text] [Related]
17. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Seol HY; Kim YS; Kim SJ
Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
[TBL] [Abstract][Full Text] [Related]
19. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
[TBL] [Abstract][Full Text] [Related]
20. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
